TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07613216: A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hy

Sponsor: Cosmos Rx, Inc · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07613216 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07613216 Rescue Dossier →